In December 2025, in a veterinary clinic in Sydney, a rescue dog named Rosie lay on a table, her tail giving a tentative wag as a veterinarian prepared an injection. The syringe contained a personalized mRNA cancer vaccine, a bespoke treatment designed not by a team of pharmaceutical researchers in a billion-dollar lab, but in large part by her owner, a tech entrepreneur who, six months earlier, could not have told you the difference between DNA and RNA.
Paul Conyngham is not a biologist. He is a Sydney-based data scientist and tech entrepreneur with seventeen years of experience in machine learning and a background in electrical and computing engineering. When his eight-year-old rescue dog Rosie was diagnosed with mast cell cancer in 2024, the prognosis was grim: one to six months to live. Chemotherapy had been tried. Surgery had been tried. Neither worked. Conyngham did what any desperate, analytically minded person might do in the age of large language models. He typed a question into ChatGPT. That question set off a chain of events no one, least of all Conyngham, could have predicted.
The chain: ChatGPT pointed him toward genomics. Researchers at the University of New South Wales agreed to help. For three thousand dollars, the UNSW Ramaciotti Centre for Genomics sequenced the DNA from Rosie's tumors and compared it to her healthy tissue. Conyngham used AlphaFold, the AI system that won the Nobel Prize for cracking biology's fifty-year protein-folding problem, to model the three-dimensional structures of the mutated proteins his dog's cancer was producing. He used Grok, another AI tool, to help design the mRNA construct for a vaccine. Professor Pall Thordarson at the UNSW RNA Institute synthesized the actual vaccine. Professor Rachel Allavena at the University of Queensland handled ethics approval and administration. Sequencing to vaccine design took less than two months. By mid-March 2026, Rosie's largest tumor had shrunk by seventy-five percent, and most of her other tumors had reduced by fifty to seventy-five percent. She had gained weight. She was chasing rabbits again.
This story sits at the intersection of several revolutions happening simultaneously. The cost of sequencing an entire genome has fallen from 2.7 billion dollars for the Human Genome Project to around two hundred dollars in 2024, a cost curve that has outpaced Moore's Law by orders of magnitude. AlphaFold's database now contains predicted structures for more than two hundred million proteins, compared to the roughly two hundred thousand experimental structures that took scientists over fifty years to accumulate. mRNA vaccine technology, proven at pandemic scale during COVID-19, has returned to its original purpose: cancer. The tools that made Rosie's story possible are, in many cases, free, open-source, and accessible to anyone with an internet connection and the willingness to learn.
This book will take you from the absolute basics (what DNA is, how genes work, what proteins do) through the cutting-edge frontier of personalized cancer vaccines, CRISPR gene editing, and AI-driven drug design. By the end, you will understand not just what happened with Rosie, but why it matters for every human on the planet, and why the next decade of medicine will look nothing like the last.
A few caveats before we begin. This book is not medical advice. It is not a do-it-yourself manual for designing cancer vaccines in your garage. Conyngham's story required institutional support at every critical step: trained scientists, university-grade equipment, ethics approval processes that took three months and a hundred pages of documentation. AI did not replace scientists; it connected a motivated outsider to their world and gave him tools to contribute. The headline "Man Uses ChatGPT to Cure Dog's Cancer" is catchy but misleading. The truth, as you will see, is both more nuanced and more inspiring.